212
Participants
Start Date
October 31, 2018
Primary Completion Date
May 3, 2022
Study Completion Date
August 2, 2023
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Local Institution - 0112, Brussels
Local Institution - 0078, CABA
Local Institution - 0113, Brussels
Local Institution - 0087, Ciudad Autónoma de Buenos Aires
Local Institution - 0015, CABA
Local Institution - 0016, Ciudad Autonoma Beunos Aires
Local Institution - 0062, Sydney
Local Institution - 0118, St Leonards
Local Institution - 0080, Copenhagen
Local Institution - 0081, Herlev
Local Institution - 0114, Leuven
Local Institution - 0117, Woolloongabba
Local Institution - 0119, Córdoba
Local Institution - 0039, Berlin
Local Institution - 0075, Marseille
Broome Oncology, Johnson City
Local Institution - 0032, Genova
IRCCS Istituto Nazionale Tumori Milano, Milan
Duke Cancer Institute, Durham
Local Institution - 0083, Madrid
Local Institution - 0110, Pamplona
Local Institution - 0074, Toulouse
Local Institution - 0086, Essen
Local Institution - 0031, Siena
Local Institution - 0001, Bonn
Local Institution - 0093, Minneapolis
Local Institution - 0072, Lyon
Local Institution - 0094, Dallas
Local Institution - 0073, Paris
Texas Oncology - Northeast Texas, Tyler
Local Institution - 0090, Houston
Local Institution - 0095, Austin
Local Institution - 0029, Napoli
Rocky Mountain Cancer Centers, Denver
John Wayne Cancer Center, Santa Monica
Local Institution - 0085, Villejuif
Local Institution - 0043, Würzburg
Local Institution - 0079, Portland
Local Institution - 0066, Singapore
Local Institution - 0065, Singapore
Local Institution - 0067, Craiova
Local Institution - 0071, Timisoara, Timis
Local Institution - 0068, Cluj-Napoca
Local Institution - 0070, Floreşti
Local Institution - 0018, Santiago
Local Institution - 0082, Santiago
Local Institution - 0010, Edmonton
Local Institution - 0060, Hamilton
Local Institution - 0036, Montreal
Local Institution - 0088, Montreal
Local Institution - 0002, Dresden
Local Institution - 0116, Rotterdam
Local Institution - 0115, Amsterdam
Local Institution - 0076, Warsaw
Local Institution - 0077, Gdansk
Fundacion De Investigacion, San Juan
Local Institution - 0069, Bucharest
Local Institution - 0084, Barcelona
Local Institution - 0106, London
Local Institution - 0107, Preston
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY